New

Alluvi (Tirzepatide)

Price range: £75.99 through £125.99

Alluvi (Tirzepatide)

A 20mg/40mg Tirzepatide formulation supplied in a pre-filled research device, provided exclusively for controlled laboratory R&D applications. Delivered in sealed format to support compound stability analysis, formulation studies, and delivery mechanism evaluation.

‍Produced for laboratory research only. Not for human or veterinary consumption.

Each Tirzepatide 20mg/40mg Research kit includes:
Pre-filled Research pen (40mg Tirzepatide)
Research information sheet

‍Storage:
Store refrigerated (2–8°C). Do not freeze.
Supplied in fixed-volume sealed format for laboratory analysis.

‍Delivery: Dispatched with a cold pack.
Tracked 2 DAY UK Delivery.

‍Research & Development purposes only

Pack Size

Strenght

Clear

SKU: N/A Category: Weight Loss

Alluvi (Tirzepatide)

Alluvi (Tirzepatide): Advanced Dual-Action Therapy for Metabolic Health

Product Overview

ALLUVI (Tirzepatide) is a revolutionary injectable medication representing a new class of treatment for managing two of the most pervasive global health challenges: Type 2 Diabetes Mellitus (T2DM) and chronic weight management in adults. As a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, ALLUVI $^{\text{TM}}$ offers a powerful, once-weekly solution designed to significantly improve blood sugar control and promote substantial weight loss when used in conjunction with a reduced-calorie diet and increased physical activity.

Available Strengths: 20 mg and 40 mg

ALLUVI is offered in two concentration strengths, 20mg and 40mg, to provide flexibility in physician-guided, individualized treatment plans. These strengths are typically used during the dose escalation and maintenance phases, following a low starting dose, as determined by a healthcare provider. The maximum recommended dose for Tirzepatide is 15mg per week. The 20mg and 40mg presentations are intended for compounding or specialized dispensing to achieve the prescribed weekly dose, ensuring patients receive the precise, medically appropriate amount as they progress through therapy. Patients should always adhere strictly to the dosing schedule and final weekly dose prescribed by their physician.

Mechanism of Action: The Power of Twincretin

Tirzepatide is often referred to as a twincretin because it mimics the action of two natural gut hormones: GIP and GLP-1. This dual mechanism provides superior efficacy compared to single-receptor agonists:

Glucose Regulation: ALLUVI enhances the body’s natural response to food by stimulating the pancreas to release insulin in a glucose-dependent manner (only when blood sugar is high). Simultaneously, it reduces the release of glucagon, a hormone that raises blood sugar, and decreases the amount of sugar produced by the liver. This multifaceted approach leads to impressive reductions in HbA_1c (a measure of average blood sugar).

Weight Management: The dual agonism targets receptors in areas of the brain that regulate appetite, leading to a reduced feeling of hunger and fewer cravings. It also slows gastric emptying, which prolongs the feeling of fullness (satiety) after meals. Clinical trials have demonstrated the robust weight-reducing effects of Tirzepatide, with some patients achieving over 20lbs weight loss from their starting body weight. The weight loss benefit is pivotal, as it addresses a key driver of T2DM progression.

Clinical Benefits

When used as part of a comprehensive management plan, ALLUVI may offer several health advantages:

Superior Glycemic Control: Achieving and maintaining target HbA_1c levels.

Significant Weight Reduction: Supporting patients in reaching meaningful weight loss goals.

Cardiometabolic Improvement: Potential for improved blood pressure and lipid profile, contributing to a reduced risk of serious complications such as heart disease and stroke.

Convenience: Administered via a simple, once-weekly subcutaneous injection.

Important Safety Information & Contraindications

As with all prescription medications, ALLUVI (Tirzepatide) carries important safety information. *Patients should be advised of the potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), as seen in rodents. ALLUVI is contraindicated in patients with a personal or family history of {MTC} or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

The most commonly reported side effects are gastrointestinal in nature and may include nausea, diarrhea, decreased appetite, vomiting, and constipation. These are typically mild to moderate in severity and decrease over time. Patients should immediately seek medical attention if they experience severe abdominal pain, which could be a sign of acute pancreatitis or gallbladder issues.

ALLUVI {TM} is a prescription-only medication and should only be used under the guidance and supervision of a qualified healthcare professional. It is not indicated for the treatment of Type 1 Diabetes Mellitus (T1DM).